Group O Leukocyte-Free Whole Blood Storage and Inflammation Study Comparing Blood Products Prepared by Two Organizations

What this Trial Is About

Researchers are studying the inflammatory and biological characteristics of blood products prepared by two different organizations the Etablissement Franais du Sang EFS, which produces standard blood components like red blood cells, plasma, and platelets, and the Centre de Transfusion Sanguine des Armes CTSA, which produces an innovative group O leukocyte-free whole blood product called LTO-WB. This research is important because hemorrhage is a major cause of preventable death in combat, and current blood component supplies may not always be available or suitable in military operations. The study compares LTO-WB with conventional blood products including platelet concentrates, red blood cell concentrates, and fresh frozen plasma, focusing on inflammation related to platelets and red blood cells. Participants donate either whole blood or plasmaplatelet products via apheresis. These donations are analyzed over time to assess inflammatory markers and biological changes during storage. Participants will be involved in blood donation procedures and subsequent laboratory analyses will measure inflammatory potential related to platelets at multiple time points during storage, from Day 2 through Day 42. The study aims to identify biomarkers that can optimize transfusion use in both military and civilian settings. This research is sponsored by Etablissement Franais du Sang and includes healthy volunteer blood donors aged 18 to 70 for whole blood and 18 to 65 for apheresis donations.

grouP O wholE blooD : storagE leSion impacT And infLammation